Skip to main content

Using PML nuclear body biology to identify potential AML treatment targets

Project description

Understanding PML nuclear bodies disruption in the context of AML treatment

A better understanding of the onset and development of acute myeloid leukaemia (AML) may lead to new therapeutic strategies. Acute promyelocytic leukaemia (APL), a subset of AML, can be successfully cured by combination therapy. Therefore, understanding the mechanisms underlying the pathogenesis and successful treatment of APL will improve the management of AML subsets with a poor prognosis. Promyelocytic leukaemia nuclear bodies (PML NBs), an archetype of membrane-less organelles that concentrate proteins at discrete sites within the nucleoplasm, are essential for APL pathogenesis and treatment response. The EU-funded PMLingAML project will elucidate the mechanisms of PML NBs disruption in APL, aiming to apply this knowledge in the treatment of other AML subsets.

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Net EU contribution
€ 184 707,84
Address
Rue De Tolbiac 101
75654 Paris
France

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Other funding
€ 0,00